EU Pharma And Cancer Associations Urge IVDR Postponement And Phased Implementation
Executive Summary
Issues with the implementation of the IVDR could delay optimal cancer treatments. Now voices representing the pharma industry and cancer patients are adding weight to the call for an IVDR delay.